News

Read about the latest publications, achievements and more from the College's faculty members!

Theodore G. Tong, PharmD, has been named to the Arizona State Board of Pharmacy effective January 2019 through 2024. Congratulations, Dr. Tong!

An interdisciplinary team of University of Arizona students was at St. Luke's recently as part of a clinic for St. Luke's elders on medication safety.

Ashley Coleman, PharmD '12, will be leading the Center. Congratulations Dr. Coleman!

Read about the latest publications, achievements and more from the College's faculty members!

UA Bachelor of Science in Pharmaceutical Sciences Students Interview NPR Correspondent and Author, Richard Harris

Pharmacogenetics expert, Jason Karnes, PharmD, PhD, BCPS, FAHA, has been named director. Congratulations Dr. Karnes!

The College of Pharmacy thanks Luann for her years of hard work and commitment, and wishes her a very happy retirement!

HOPE Center doctoral students and faculty collaborate in this new cost-effectiveness study.

Insight from Dr. Khalid Eljaaly, a post-doctoral fellow alumni.

Alexandria Lau, PhD ’12, has worked for SC Johnson, the Hershey Company, and now, a winery.

The initiative includes evolving PharmD course curriculum and providing specialized training in key areas where additional expertise is needed.

Dr. Hurley received the recognition on behalf of the Arizona Technology Council and the Arizona Commerce Authority.

Read about the latest publications, achievements and more from the College's faculty members!

After 26 years, Marty Baker is retiring from the College of Pharmacy.

Named in honor of Dr. Glenn Sipes, the award will enable its graduate students to advance their research by participating in scientific meetings.

Health and Pharmaceutical Outcomes graduate student, Srujitha Marupuru, PharmD presented her research at the 2018 ACCP Global Conference.

Congratulations to the new PediaCATS 2018-2019 Executive Board!

Read about the latest publications, achievements and more from the College's faculty members!

Though there are currently only 12 biosimilars approved by the Food and Drug Administration (FDA), there are many more in the pipeline, and the oncology world is bracing itself for their impact. How will they be incorporated into practice? What will it mean for the health care ecosystem?